PT2332989E - Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas - Google Patents

Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas Download PDF

Info

Publication number
PT2332989E
PT2332989E PT100098573T PT10009857T PT2332989E PT 2332989 E PT2332989 E PT 2332989E PT 100098573 T PT100098573 T PT 100098573T PT 10009857 T PT10009857 T PT 10009857T PT 2332989 E PT2332989 E PT 2332989E
Authority
PT
Portugal
Prior art keywords
methods
enhanced stability
intracellular environment
demonstrate enhanced
immunoglobulin frameworks
Prior art date
Application number
PT100098573T
Other languages
English (en)
Portuguese (pt)
Inventor
Stefan Ewert
Alcide Barberis
Adrian Auf Der Maur
Kathrin Tissot
Dominik Escher
Original Assignee
Esbatech Alcon Biomed Res Unit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech Alcon Biomed Res Unit filed Critical Esbatech Alcon Biomed Res Unit
Publication of PT2332989E publication Critical patent/PT2332989E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT100098573T 2002-05-22 2003-05-21 Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas PT2332989E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38264902P 2002-05-22 2002-05-22
US43825603P 2003-01-03 2003-01-03

Publications (1)

Publication Number Publication Date
PT2332989E true PT2332989E (pt) 2015-08-05

Family

ID=29553590

Family Applications (2)

Application Number Title Priority Date Filing Date
PT100098573T PT2332989E (pt) 2002-05-22 2003-05-21 Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas
PT37324340T PT1506236E (pt) 2002-05-22 2003-05-21 Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT37324340T PT1506236E (pt) 2002-05-22 2003-05-21 Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas

Country Status (14)

Country Link
US (5) US8853362B2 (OSRAM)
EP (5) EP1506236B1 (OSRAM)
JP (10) JP2006508638A (OSRAM)
CN (4) CN1662556B (OSRAM)
AU (2) AU2003238370B2 (OSRAM)
CA (2) CA2483285C (OSRAM)
CY (1) CY1114225T1 (OSRAM)
DK (2) DK1506236T3 (OSRAM)
ES (3) ES2537104T3 (OSRAM)
HU (1) HUE048922T2 (OSRAM)
NZ (1) NZ536412A (OSRAM)
PT (2) PT2332989E (OSRAM)
SI (2) SI2947095T1 (OSRAM)
WO (1) WO2003097697A2 (OSRAM)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
EP2351842A1 (en) 2005-03-25 2011-08-03 National Research Council Of Canada Method for isolation of soluble polypeptides
PL2390267T3 (pl) 2005-06-07 2013-09-30 Esbatech A Novartis Co Llc Stabilne i rozpuszczalne przeciwciała hamujące TNF(alfa)
AU2016204739C1 (en) * 2005-06-07 2017-10-19 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
AU2013207650B2 (en) * 2005-06-07 2016-04-21 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
AU2011265593B2 (en) * 2005-06-07 2013-08-15 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
CN101443361B (zh) * 2006-04-28 2015-08-19 德勒尼克斯治疗股份公司 与受体酪氨酸激酶alk的胞外域结合的抗体
CA2658241C (en) 2006-07-10 2018-01-02 Esbatech Ag Scfv antibodies which pass epithelial and/or endothelial layers
US8280711B2 (en) 2007-03-12 2012-10-02 ESBATech, an Alcon Biomedical Research Unit, LLC. Sequence based engineering and optimization of single chain antibodies
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
KR101573086B1 (ko) * 2007-06-25 2015-11-30 에스바테크 - 어 노바티스 컴파니 엘엘씨 항체를 변형시키는 방법, 및 기능적 특성이 개선된 변형된 항체
NZ581470A (en) 2007-06-25 2013-04-26 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
JP5500730B2 (ja) 2007-09-13 2014-05-21 デレネックス セラピューティクス アーゲー β−アミロイドペプチドに対するヒト化抗体
LT3216803T (lt) 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
MX2011000052A (es) 2008-06-25 2011-07-29 Esbatech Alcon Biomed Res Unit Humanizacion de anticuerpos de conejos usando una estructura de anticuerpos universal.
HUE047678T2 (hu) * 2008-06-25 2020-05-28 Novartis Ag Nyúl ellenanyagok humanizálása univerzális ellenanyagváz alkalmazásával
AU2015201794B2 (en) * 2008-06-25 2017-01-19 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
AU2016273957C1 (en) * 2008-06-25 2019-04-18 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
AU2009264564B2 (en) 2008-06-25 2014-05-08 Novartis Ag Stable and soluble antibodies inhibiting TNFalpha
RU2514658C2 (ru) 2008-06-25 2014-04-27 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Оптимизация растворимости иммуносвязывающих средств
AU2013202997B2 (en) * 2008-06-25 2015-01-22 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFalpha
SI2752428T1 (sl) * 2008-06-25 2020-03-31 Novartis Ag Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa
KR101678925B1 (ko) * 2008-06-30 2016-11-24 에스바테크 - 어 노바티스 컴파니 엘엘씨 기능화 폴리펩티드
EP2769711A1 (en) 2008-07-10 2014-08-27 ESBATech, an Alcon Biomedical Research Unit LLC Methods and Compositions for Enhanced Delivery of Macromolecules
MX352922B (es) * 2009-02-24 2017-12-14 Esbatech Alcon Biomed Res Unit Métodos para identificar inmunoligadores de los antígenos de la superficie celular.
AU2010217120B2 (en) 2009-02-24 2014-11-20 Novartis Ag Methods for identifying immunobinders of cell-surface antigens
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
EP2476754A1 (en) * 2011-01-14 2012-07-18 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv)
EP2744931B1 (en) 2011-08-18 2018-05-02 Affinity Biosciences Pty Ltd Soluble polypeptides
CN109608543A (zh) 2011-10-20 2019-04-12 艾斯巴技术-诺华有限责任公司 稳定的多抗原结合抗体
CN113234142B (zh) * 2012-08-22 2024-03-05 财团法人牧岩生命工学研究所 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
EP3750917A1 (en) 2012-11-05 2020-12-16 Delenex Therapeutics AG Binding members to il-1 beta
ES2895848T3 (es) 2012-12-17 2022-02-22 Cell Medica Inc Anticuerpos contra IL-1 beta
EP2956478A1 (en) * 2013-02-15 2015-12-23 ESBATech - a Novartis Company LLC Acceptor framework for cdr grafting
RU2015139890A (ru) * 2013-02-20 2017-03-27 ИЭсБиЭйТЕК - Э НОВАРТИС КОМПАНИ ЭлЭлСи Акцепторный каркасный участок для пересадки cdr
SG10201800800YA (en) 2013-05-06 2018-03-28 Scholar Rock Inc Compositions and methods for growth factor modulation
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
CA2967595A1 (en) 2014-11-12 2016-05-19 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX2018004515A (es) * 2015-10-13 2019-04-15 Eureka Therapeutics Inc Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
CN107614519B (zh) 2015-10-23 2022-08-05 优瑞科生物技术公司 抗体/t细胞受体嵌合构建体及其用途
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3420000A1 (en) 2016-02-25 2019-01-02 Cell Medica Switzerland AG Modified cells for immunotherapy
MX2019003225A (es) * 2016-09-21 2019-06-10 Aptevo Res & Development Llc Proteínas de unión a cd123 y composiciones y métodos relacionados.
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
JP2020510671A (ja) 2017-03-03 2020-04-09 シアトル ジェネティックス， インコーポレイテッド グリカン相互作用化合物および使用の方法
JP7416433B2 (ja) * 2018-04-10 2024-01-17 ノースウェスタン ユニバーシティ 標的指向性親和性ドメインに基づく膜タンパク質を含む細胞外小胞
US20200102373A1 (en) * 2018-09-27 2020-04-02 Colorado State University Research Foundation Scfv's for live cell imaging and other uses
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
MX2023000547A (es) 2020-07-16 2023-02-13 Novartis Ag Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas.
US20240150449A1 (en) 2021-03-10 2024-05-09 Mabylon Ag Antibodies against tdp-43 and methods of using the same
US20250101089A1 (en) 2022-01-24 2025-03-27 Cambridge Enterprise Limited Tau therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
US7264963B1 (en) * 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
US6262238B1 (en) 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
EP1040201A4 (en) 1997-11-28 2001-11-21 Invitrogen Corp SINGLE CHAIN MONOCLONAL ANTIBODY FUSION AGENTS THAT REGULATE IN VIVO TRANSCRIPTION
GB2344886B (en) 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
DK1242457T3 (da) 1999-12-28 2004-12-20 Esbatech Ag Intracellulære antistoffer [intracellulære antistoffer] med defineret struktur, der er stabil i et reducerende miljö, og anvendelse deraf
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
EP1156062A1 (en) 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
DE10039191C1 (de) 2000-08-10 2002-01-17 Infineon Technologies Ag Hochfrequenz-Eingangsstufe

Also Published As

Publication number Publication date
US20170107272A1 (en) 2017-04-20
AU2010202634A1 (en) 2010-07-15
US20150057191A1 (en) 2015-02-26
JP6100544B2 (ja) 2017-03-22
CN103739706B (zh) 2015-11-18
US10125186B2 (en) 2018-11-13
EP2332989A1 (en) 2011-06-15
US10570190B2 (en) 2020-02-25
AU2010202634B2 (en) 2012-08-23
CN102093477B (zh) 2014-02-26
CN103739706A (zh) 2014-04-23
ES2656427T3 (es) 2018-02-27
JP2013078343A (ja) 2013-05-02
PT1506236E (pt) 2013-03-27
EP3656787A1 (en) 2020-05-27
CA2867542C (en) 2020-04-14
US8853362B2 (en) 2014-10-07
JP6918033B2 (ja) 2021-08-11
NZ536412A (en) 2008-10-31
US20200165322A1 (en) 2020-05-28
DK2332989T3 (en) 2015-05-11
CN105175535A (zh) 2015-12-23
EP1506236B1 (en) 2013-01-23
CA2483285A1 (en) 2003-11-27
ES2537104T3 (es) 2015-06-02
JP2017201990A (ja) 2017-11-16
CY1114225T1 (el) 2016-08-31
CN1662556A (zh) 2005-08-31
WO2003097697A2 (en) 2003-11-27
JP2010187678A (ja) 2010-09-02
WO2003097697A3 (en) 2004-12-09
JP2012228272A (ja) 2012-11-22
HK1071378A1 (en) 2005-07-15
AU2003238370B2 (en) 2010-04-29
EP2332989B1 (en) 2015-04-01
JP2015214583A (ja) 2015-12-03
JP2020171286A (ja) 2020-10-22
US20190119361A1 (en) 2019-04-25
DK1506236T3 (da) 2013-03-04
CN1662556B (zh) 2013-05-01
JP2013256533A (ja) 2013-12-26
JP6075836B2 (ja) 2017-02-08
CN102093477A (zh) 2011-06-15
EP2314622B1 (en) 2017-10-18
US20060035320A1 (en) 2006-02-16
CA2483285C (en) 2015-01-27
HK1152320A1 (en) 2012-02-24
JP2006508638A (ja) 2006-03-16
SI2947095T1 (sl) 2020-04-30
US9518108B2 (en) 2016-12-13
JP2019058191A (ja) 2019-04-18
HUE048922T2 (hu) 2020-09-28
EP2947095A1 (en) 2015-11-25
CA2867542A1 (en) 2003-11-27
JP6261136B2 (ja) 2018-01-17
JP2015227372A (ja) 2015-12-17
EP2947095B1 (en) 2019-10-02
EP2314622A1 (en) 2011-04-27
EP1506236A2 (en) 2005-02-16
SI2332989T1 (sl) 2015-06-30
HK1217712A1 (en) 2017-01-20
ES2399617T3 (es) 2013-04-02
AU2003238370A1 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
HUE048922T2 (hu) Immunglobulin vázrégiók, amelyek intracelluláris környezetben fokozott stabilitást mutatnak, továbbá eljárások azonosításukra
TWI370816B (en) 6-alkyl or alkenyl-4-aminopicolinates and their use as herbicides
EP1546112A4 (en) IMIDAZOLOPYRIDINE AND METHOD FOR THE PRODUCTION AND USE THEREOF
AU2003282478A8 (en) Discount-instrument methods and systems
AU2003267279A8 (en) Systems and methods for transformable suits
PL381765A1 (pl) Konstrukty wiążące i sposoby ich zastosowania
IL225633A0 (en) Antibodies against alpha v beta 6 and uses thereof
EP1551447A4 (en) ANTI-ADDL ANTIBODIES AND USES THEREOF
GB0619264D0 (en) Methods and lens
EP1539941A4 (en) ADZYMES AND THEIR USES
ZA200603882B (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
EP1596656A4 (en) PYRAZOLES AND METHODS OF MAKING AND USING THEM
IL175491A0 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
EP1550923A4 (en) THREE-DIMENSIONAL DISPLAY AND METHOD FOR THREE-DIMENSIONAL DISPLAY
EG24579A (en) Herbicide composition and weed-controlling method using the same
AU2003265562A8 (en) Computer-aided education systems and methods
GB0202059D0 (en) Chemical compositions and methods
IL172510A0 (en) Antibodies and uses thereof
AU2002346446A8 (en) Methods and compositions in checkpoint signaling
IL166063A0 (en) Antibodies and uses thereof
AU2003297612A8 (en) 2-substituted-3-propenamide derivatives and methods of using the same
SG112011A1 (en) Laser micromachining and methods of same
AU2003231827A8 (en) Pseudo-tissues and uses thereof
EP1418194A4 (en) MODIFIED POLYALKYLENEIMINE AND METHODS OF USE
GB0318546D0 (en) Quinoxalinones and their use